Ubs Asset Management Americas Inc Lyell Immunopharma, Inc. Transaction History
Ubs Asset Management Americas Inc
- $345 Billion
- Q2 2024
A detailed history of Ubs Asset Management Americas Inc transactions in Lyell Immunopharma, Inc. stock. As of the latest transaction made, Ubs Asset Management Americas Inc holds 192,609 shares of LYEL stock, worth $265,800. This represents 0.0% of its overall portfolio holdings.
Number of Shares
192,609
Previous 33,000
483.66%
Holding current value
$265,800
Previous $73,000
282.19%
% of portfolio
0.0%
Previous 0.0%
Shares
2 transactions
Others Institutions Holding LYEL
# of Institutions
123Shares Held
145MCall Options Held
2.6KPut Options Held
7.5K-
Mwg Management Ltd. Washington, DC20.2MShares$27.8 Million31.93% of portfolio
-
Apoletto LTD Washington, DC15.1MShares$20.8 Million42.56% of portfolio
-
Orland Properties LTD Washington, DC15.1MShares$20.8 Million16.63% of portfolio
-
Black Rock Inc. New York, NY13.5MShares$18.6 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA13.4MShares$18.5 Million0.0% of portfolio
About Lyell Immunopharma, Inc.
- Ticker LYEL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 247,824,992
- Market Cap $342M
- Description
- Lyell Immunopharma, Inc., a T cell reprogramming company, engages in developing T cell therapies for patients with solid tumors. The company develops therapies using technology platforms, such as Gen-R, an ex vivo genetic reprogramming technology to overcome T cell exhaustion; and Epi-R, an ex vivo epigenetic reprogramming technology to generate...